Skip to Main Content
Advertisement
Close
ASH Clinical News
ASH News Daily
ASH-SAP
Blood
Blood Advances
Hematology
The Hematologist
International
Blood Chinese Edition
Blood Japanese Edition
Blood Italian Edition
Blood Latin America Edition
Blood Spanish Edition
ASH
ASH Home
Research
Education
Advocacy
Meetings
Publications
ASH Store
Cart
User Tools Dropdown
Cart
Sign In
Search Dropdown Menu
header search
search input
Search input auto suggest
filter your search
All Content
All Journals
Blood Advances
Search
Toggle Menu
Menu
Issues
Current Issue
All Issues
Latest Articles
First Edition
Latest Articles
Guidelines
Collections
Collections
Special Collections
Multimedia
Alerts
Author Center
Submit
Author Guide
Style Guide
About
About Blood Advances
Editorial Board and Staff
Copyright
Alerts
Skip Nav Destination
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Blood Adv
(2021) 5 (5): 1552–1564.
Currently there are no citedby results. Try again later.
Close Modal
Close Modal
This Feature Is Available To Subscribers Only
Sign In
or
Create an Account
Close Modal
Close Modal
Advertisement
close advertisement
